IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Phase 2 Completed 81 enrolled Innovent Biologics (Suzhou) Co. Ltd.

NaSingle-groupOpen-labelTreatment

Summary

A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Timeline

Start: 2020-04-07
Primary completion: 2021-07-27
Completion: 2023-11-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Parsaclisib	Small molecule	2.5 mg	Oral

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Summary

Timeline

Drugs

Indications